Mego M - Search Results

1

Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I. Mardiak J, et al. Among authors: mego m. Neoplasma. 2005;52(3):243-7. Neoplasma. 2005. PMID: 15875087 Clinical Trial.

2

Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.

Mego M, Ebringer L, Drgona L, Mardiak J, Trupl J, Greksak R, Nemova I, Oravcova E, Zajac V, Koza I. Mego M, et al. Neoplasma. 2005;52(2):159-64. Neoplasma. 2005. PMID: 15800715 Clinical Trial.

3

Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I. Mardiak J, et al. Among authors: mego m. Neoplasma. 2005;52(6):497-501. Neoplasma. 2005. PMID: 16284696 Clinical Trial.

4

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Recková M, Mego M, Hlavatá Z, Brozmanová K, Risnyovzská Z, Svetlovská D, Koza I. Mardiak J, et al. Among authors: mego m. Neoplasma. 2007;54(3):240-5. Neoplasma. 2007. PMID: 17447857 Clinical Trial.

5

Prognostic factors in patients with relapsed or primary refractory germ cell tumors.

Rejlekova K, Mego M, Sycova-Mila Z, Obertova J, Rajec J, Salek T, Mardiak J. Rejlekova K, et al. Among authors: mego m. Neoplasma. 2009;56(3):215-23. doi: 10.4149/neo_2009_03_215. Neoplasma. 2009. PMID: 19309224

6

Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.

Mego M, Rejlekova K, Reckova M, Sycova-Mila Z, Obertova J, Rajec J, Mardiak J. Mego M, et al. Neoplasma. 2009;56(5):398-403. doi: 10.4149/neo_2009_05_398. Neoplasma. 2009. PMID: 19580341

7

Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial.

Mego M, Svetlovska D, Reckova M, Angelis D, Kalavska K, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Chovanec M, Mardiak J. Mego M, et al. Invest New Drugs. 2021 Dec;39(6):1664-1670. doi: 10.1007/s10637-021-01130-5. Epub 2021 May 29. Invest New Drugs. 2021. PMID: 34052929 Clinical Trial.

8

Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.

Mego M, Svetlovska D, Angelis V D, Kalavska K, Lesko P, Makovník M, Obertova J, Orszaghova Z, Palacka P, Rečková M, Rejlekova K, Z SM, Mardiak J, Chovanec M. Mego M, et al. Invest New Drugs. 2022 Oct;40(5):1080-1086. doi: 10.1007/s10637-022-01271-1. Epub 2022 Jun 28. Invest New Drugs. 2022. PMID: 35763178 Clinical Trial.

9

Small-cell carcinoma of the ovary with breast metastases: a case report.

Reckova M, Mego M, Rejlekova K, Sycova-Mila Z, Obertova Z, Mardiak J. Reckova M, et al. Among authors: mego m. Klin Onkol. 2010;23(1):43-5. Klin Onkol. 2010. PMID: 20192073

10

The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.

Palacka P, Mego M, Obertova J, Chovanec M, Sycova-Mila Z, Mardiak J. Palacka P, et al. Among authors: mego m. Klin Onkol. 2014;27(6):429-33. doi: 10.14735/amko2014429. Klin Onkol. 2014. PMID: 25493582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

232 results

Search Page

Filters